Continuous renal replacement therapy (CRRT) is intended to function continuously and is prescribed for this outcome. Anticoagulants may not always be used. Clotting and clogging within the CRRT filter stopping therapy occurs with a variability in the total elapsed time associated. This is commonly known as the circuit or filter “life”. It is very useful and important to record this time at the bedside and refer to this as a measure of success and quality. Filter life (i.e., hours) is reported in many reports investigating CRRT but is not well understood or clear for when this is considered inadequate and clinical review strategies should be considered. Failure before 8 h could be associated with inadequate renal support and “therapy”. Anticoagulation is the key intervention to prolong filter function; however, the extracorporeal circuit design and set up, access catheter profile and insertion site, CRRT machine settings, and the human interface operating CRRT are always important and the only consideration to prevent failure when no anticoagulation is mandated for CRRT.

1.
Rewa OG, Villeneuve PM, Lachance P, Eurich DT, Stelfox HT, Gibney RT, et al. Quality indicators of continuous renal replacement therapy (CRRT) care in critically ill patients: a systematic review. Intensive Care Med. 2017 Jun;43(6):750–63.
2.
Khwaja A. KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pract. 2012;120(4):c179–84.
3.
Fealy N, Baldwin I, Bellomo R. The effect of circuit “down-time” on uraemic control during continuous veno-venous haemofiltration. Crit Care Resusc. 2002 Dec;4(4):266–70.
4.
Bagshaw SM, Chakravarthi MR, Ricci Z, Tolwani A, Neri M, De Rosa S, et al.; ADQI Consensus Group. Precision Continuous Renal Replacement Therapy and Solute Control. Blood Purif. 2016;42(3):238–47.
5.
Rewa OG, Eurich DT, Noel Gibney RT, Bagshaw SM. A modified Delphi process to identify, rank and prioritize quality indicators for continuous renal replacement therapy (CRRT) care in critically ill patients. J Crit Care. 2018 Oct;47:145–52.
6.
Neri M, Villa G, Garzotto F, Bagshaw S, Bellomo R, Cerda J, et al.; Nomenclature Standardization Initiative (NSI) alliance. Nomenclature for renal replacement therapy in acute kidney injury: basic principles. Crit Care. 2016 Oct;20(1):318.
7.
Villa G, Neri M, Bellomo R, Cerda J, De Gaudio AR, De Rosa S, et al.; Nomenclature Standardization Initiative (NSI) Alliance. Nomenclature for renal replacement therapy and blood purification techniques in critically ill patients: practical applications. Crit Care. 2016 Oct;20(1):283.
8.
Rewa OG, Tolwani A, Mottes T, Juncos LA, Ronco C, Kashani K, et al.; ADQI Consensus Meeting Members on behalf of ADQI XXII. Quality of care and safety measures of acute renal replacement therapy: workgroup statements from the 22nd acute disease quality initiative (ADQI) consensus conference. J Crit Care. 2019 Dec;54:52–7.
9.
Uchino S, Fealy N, Baldwin I, Morimatsu H, Bellomo R. Continuous venovenous hemofiltration without anticoagulation. ASAIO J. 2004 Jan-Feb;50(1):76–80.
10.
Bellomo R, Ronco C, Mehta RL. Nomenclature for continuous renal replacement therapies. Am J Kidney Dis. 1996;28(5):S2–7.
11.
Fealy N, Aitken L, du Toit E, Lo S, Baldwin I. Faster Blood Flow Rate Does Not Improve Circuit Life in Continuous Renal Replacement Therapy: A Randomized Controlled Trial. Crit Care Med. 2017 Oct;45(10):e1018–25.
12.
Gattas DJ, Rajbhandari D, Bradford C, Buhr H, Lo S, Bellomo R. A Randomized Controlled Trial of Regional Citrate Versus Regional Heparin Anticoagulation for Continuous Renal Replacement Therapy in Critically Ill Adults. Crit Care Med. 2015 Aug;43(8):1622–9.
13.
Palevsky PM, Zhang JH, O’Connor TZ, Chertow GM, Crowley ST, Choudhury D, et al.; VA/NIH Acute Renal Failure Trial Network. Intensity of renal support in critically ill patients with acute kidney injury. N Engl J Med. 2008 Jul;359(1):7–20.
14.
Bellomo R, Cass A, Cole L, Finfer S, Gallagher M, Lo S, et al.; RENAL Replacement Therapy Study Investigators. Intensity of continuous renal-replacement therapy in critically ill patients. N Engl J Med. 2009 Oct;361(17):1627–38.
15.
Tolwani AJ, Wille KM. Anticoagulation for continuous renal replacement therapy. Semin Dial. 2009 Mar-Apr;22(2):141–5.
16.
Tolwani A, Wille KM. Regional citrate anticoagulation for continuous renal replacement therapy: the better alternative? Am J Kidney Dis. 2012 Jun;59(6):745–7.
17.
Dirkes S, Wonnacott R. Continuous Renal Replacement Therapy and Anticoagulation: What Are the Options? Crit Care Nurse. 2016 Apr;36(2):34–41.
18.
Meersch M, Küllmar M, Wempe C, Kindgen-Milles D, Kluge S, Slowinski T, et al.; SepNet Critical Care Trials Group. Regional citrate versus systemic heparin anticoagulation for continuous renal replacement therapy in critically ill patients with acute kidney injury (RICH) trial: study protocol for a multicentre, randomised controlled trial. BMJ Open. 2019 Jan;9(1):e024411.
19.
Digvijay K, Neri M, Fan W, Ricci Z, Ronco C. International Survey on the Management of Acute Kidney Injury and Continuous Renal Replacement Therapies: Year 2018. Blood Purif. 2019;47(1-3):113–9.
20.
Fealy N, Aitken L, Toit E, Baldwin I. Continuous renal replacement therapy: current practice in Australian and New Zealand intensive care units. Crit Care Resusc. 2015 Jun;17(2):83–91.
21.
Karakala N, Tolwani A. We Use Heparin as the Anticoagulant for CRRT. Semin Dial. 2016 Jul;29(4):272–4.
22.
Baldwin I, Tan HK, Bridge N, Bellomo R. Possible strategies to prolong circuit life during hemofiltration: three controlled studies. Ren Fail. 2002 Nov;24(6):839–48.
23.
Zhang L, Tanaka A, Zhu G, Baldwin I, Eastwood GM, Bellomo R. Patterns and Mechanisms of Artificial Kidney Failure during Continuous Renal Replacement Therapy. Blood Purif. 2016;41(4):254–63.
24.
Baldwin I, Bellomo R, Koch B. Blood flow reductions during continuous renal replacement therapy and circuit life. Intensive Care Med. 2004 Nov;30(11):2074–9.
25.
Baldwin I, Fealy N. Clinical nursing for the application of continuous renal replacement therapy in the intensive care unit. Semin Dial. 2009 Mar-Apr;22(2):189–93.
26.
Baldwin I, Fealy N. Nursing for renal replacement therapies in the Intensive Care Unit: historical, educational, and protocol review. Blood Purif. 2009;27(2):174–81.
27.
Mottes TA, Goldstein SL, Basu RK. Process based quality improvement using a continuous renal replacement therapy dashboard. BMC Nephrol. 2019 Jan;20(1):17.
28.
Sagedal S, Witczak BJ, Osnes K, Hartmann A, Os I, Eikvar L, et al. A heparin-coated dialysis filter (AN69 ST) does not reduce clotting during hemodialysis when compared to a conventional polysulfone filter (F×8). Blood Purif. 2011;32(3):151–5.
29.
Morgan D, Ho K, Murray C, Davies H, Louw J. A randomized trial of catheters of different lengths to achieve right atrium versus superior vena cava placement for continuous renal replacement therapy. Am J Kidney Dis. 2012 Aug;60(2):272–9.
30.
Kim IB, Fealy N, Baldwin I, Bellomo R. Insertion side, body position and circuit life during continuous renal replacement therapy with femoral vein access. Blood Purif. 2011;31(1-3):42–6.
31.
Crosswell A, Brain MJ, Roodenburg O. Vascular access site influences circuit life in continuous renal replacement therapy. Crit Care Resusc. 2014 Jun;16(2):127–30.
32.
Schetz M, Van Cromphaut S, Dubois J, Van den Berghe G. Does the surface-treated AN69 membrane prolong filter survival in CRRT without anticoagulation? Intensive Care Med. 2012 Nov;38(11):1818–25.
33.
Uchino S, Fealy N, Baldwin I, Morimatsu H, Bellomo R. Pre-dilution vs. post-dilution during continuous veno-venous hemofiltration: impact on filter life and azotemic control. Nephron Clin Pract. 2003;94(4):c94–8.
34.
Ede J, Dale A. A service evaluation comparing CVVH an CVVHD in minimising circuit failure. Nurs Crit Care. 2017 Jan;22(1):52–7.
35.
Boyle M, Baldwin I. Understanding the continuous renal replacement therapy circuit for acute renal failure support: a quality issue in the intensive care unit. AACN Adv Crit Care. 2010 Oct-Dec;21(4):367–75.
36.
Baldwin I, Fealy N, Carty P, Boyle M, Kim I, Bellomo R. Bubble chamber clotting during continuous renal replacement therapy: vertical versus horizontal blood flow entry. Blood Purif. 2012;34(3-4):213–8.
37.
Gretz N, Quintel M, Ragaller M, Odenwälder W, Bender HJ, Rohmeiss P, et al. Low-dose heparinization for anticoagulation in intensive care patients on continuous hemofiltration. Contrib Nephrol. 1995;116:130–5.
38.
Graham P, Lischer E. Nursing issues in renal replacement therapy: organization, manpower assessment, competency evaluation and quality improvement processes. Semin Dial. 2011 Mar-Apr;24(2):183–7.
39.
Baldwin I. Is there a need for a nurse emergency team for continuous renal replacement therapy? Contrib Nephrol. 2007;156:191–6.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.